ClinicaliQ Trial Snapshot
- Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets — Recruiting • Respiratory / COPD / Asthma • NCT07112235.
- What is being tested: Multi-omics analysis of rhinovirus-induced COPD exacerbations to identify underlying biological mechanisms and develop novel therapeutic targets and treatments for this common trigger of disease flare-ups.
- Patient eligibility overview: The study enrolls patients with established COPD who experience acute exacerbations (symptom flare-ups), with particular focus on those triggered by rhinovirus infection, a common respiratory pathogen.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses. The main questions the study aims to answer are: * What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop…
Eligibility Snapshot
- for COPD subjects * Male or female sex * Age ≥40 years and ≤75 years at the time of signing the consent form * Medical history or clinical diagnosis of COPD * Significant smoking history, defined as: * Cumulative smoking history of at least 20 pack years * Permitted to currently use, or have history of use of, e-cigarettes/vapes * COPD spirometry criteria: * Post bronchodilator FEV1 of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.